Published financial brief
2515B
HOOKIPA PHARMA INC
- As of
- 2024-12-31
- Source
- Supabase fundamentals
- Calculator
- financial-roic-1.0.0
- Published
- 7/26/2026
2 data notes
- Input provenance requires review.
- One or more values are unavailable.
Exact-period record
Fundamentals
5 reported periods
| Metric | FY 20202020-12-31 | FY 20212021-12-31 | FY 20222022-12-31 | FY 20232023-12-31 | FY 20242024-12-31 |
|---|---|---|---|---|---|
| Financial statements | |||||
| RevenueUSD millions | 19.6 | 18.4 | 14.2 | 20.1 | 43.9 |
| Cost of goods soldUSD millions | 68.7 | 95.5 | 83.8 | 101.5 | 86 |
| Selling, general and administrative expenseUSD millions | —missing | —missing | —missing | —missing | —missing |
| Depreciation and amortizationUSD millions | 4.2 | 4.6 | 3.6 | 3.6 | 2.8 |
| Net incomeUSD millions | -44.1 | -75.7 | -64.9 | -81.6 | -43.5 |
| Operating profit (EBIT)USD millions | -53.3 | -81.7 | -73.2 | -84.9 | -44.8 |
| Income taxesUSD millions | 0 | 0 | 0.2 | 0.4 | -0.1 |
| Short-term debtUSD millions | 2.2 | 4.5 | 3.3 | 2.8 | 0.6 |
| Long-term debtUSD millions | 8.6 | 6.1 | 3.2 | 3.8 | 0.3 |
| Cash and equivalentsUSD millions | 142.7 | 66.5 | 113 | 117.1 | 39.8 |
| ReceivablesUSD millions | 20.7 | 21.2 | 22 | 19.3 | 23.7 |
| InventoryUSD millions | 0 | 0 | 0 | 0 | 0 |
| PayablesUSD millions | 8 | 8.8 | 5.5 | 12.5 | 8.7 |
| Net property, plant and equipmentUSD millions | 14 | 22.1 | 22 | 13.2 | 1.1 |
| Capital expenditureUSD millions | 2.4 | 12.6 | 5 | 4.2 | 0.2 |
| Operating cash flowUSD millions | -39.3 | -66 | -20 | -57.5 | -77 |
| Prepaid expensesUSD millions | —missing | —missing | —missing | —missing | —missing |
| AccrualsUSD millions | 5.1 | 7.8 | 9.1 | 10.9 | 10.1 |
| EBITDAUSD millions | -49.1 | -77 | -69.6 | -81.4 | -42 |
| Working capitalUSD millions | 150.4 | 74.5 | 111.6 | 105.1 | 56 |
| Working capital requirementUSD millions | 12.6 | 12.4 | 16.5 | 6.8 | 15 |
| Total debtUSD millions | 10.8 | 10.6 | 6.5 | 6.6 | 0.9 |
| Free cash flowUSD millions | -41.7 | -78.6 | -25 | -61.7 | -77.2 |
| Unlevered free cash flowUSD millions | -55.4 | -89.4 | -78.7 | -75.8 | -50.3 |
| Returns and ratios | |||||
| ROICratio | -200.2% | -236.6% | -190% | -424.9% | -278.4% |
| Pre-tax ROICratio | -200.2% | -236.6% | -190% | -424.9% | -279.1% |
| Effective tax rateratio | 0% | 0% | 0% | 0% | 0.2% |
| Revenue growthratio | 64% | -5.8% | -22.8% | 41.3% | 118.3% |
| EBIT / Revenueratio | -272.1% | -442.7% | -513.4% | -421.9% | -101.9% |
| Revenue / Invested capitalmultiple | 0.74× | 0.53× | 0.37× | 1.01× | 2.74× |
| Cogs Over Revenuesratio | 350.9% | 517.6% | 588.1% | 504.3% | 195.7% |
| Sga Over Revenuesratio | —missing | —missing | —missing | —missing | —missing |
| Da Over Revenuesratio | 21.2% | 25.2% | 25.3% | 17.6% | 6.3% |
| Nfa Over Revenuesratio | 71.3% | 119.9% | 154.2% | 65.7% | 2.4% |
| Wcr Over Revenuesratio | 64.6% | 67.2% | 116% | 33.6% | 34.1% |
| Debt Over Ebitdamultiple | —missing | —missing | —missing | —missing | —missing |
| St Debt Over Cashmultiple | 0.02× | 0.07× | 0.03× | 0.02× | 0.01× |
| Interest Over Ebitdamultiple | —missing | —missing | —missing | —missing | —missing |
| Interest Over Nocf Nicfmultiple | -0.02× | -0.01× | -0.03× | -0.01× | -0× |
| Nsf Over Wcrmultiple | -11.12× | -5× | -6.64× | -16.88× | -2.62× |
Ask this snapshot
Research assistant
2515B · annualSnapshot 63b6b4f0
Answers use only this published snapshot. The assistant will say when the data is insufficient and does not create forecasts, scenarios, or investment advice.
0 / 2,000